NCT06227897 2024-12-10
AERESA
Sun Yat-sen University
Phase 2 Withdrawn
Clinical Trials
11 trialsNCT04808752 2024-04-22
ACHIEVE
Zhejiang Cancer Hospital
Phase 2 Active not recruiting
NCT05946460 2024-02-06
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT04841811 2023-11-18
APPROACH
Guangdong Association of Clinical Trials
Phase 3 Recruiting
NCT05994339 2023-08-29
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
Laibin People's Hospital
Phase 2/3 Unknown
NCT05826483 2023-04-24
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
NCT04922138 2023-04-21
APPOINT
Shanghai Chest Hospital
Phase 2 Unknown
NCT04519983 2023-03-20
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT04882345 2021-05-11
ACTIVE
Shanghai Chest Hospital
Phase 2 Unknown
NCT04636593 2021-01-12
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04592666 2020-10-19
APPEAL
Fudan University
Phase 2 Unknown